• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: PULMONX CORPORATION ZEPHYR ENDOBRONCHIAL VALVE (EBV)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

PULMONX CORPORATION ZEPHYR ENDOBRONCHIAL VALVE (EBV) Back to Search Results
Model Number ZEPHYR 4.0-LP EBV
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Pneumothorax (2012); Sepsis (2067)
Event Date 11/16/2022
Event Type  Injury  
Manufacturer Narrative
Pneumothorax is the most common side effect associated with the zephyr valve treatment (criner et al.A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate).Am j respir crit care med.2018; 198 (9): 1151-1164).Targeted lobar deflation likely causes inflation of the ipsilateral lobe, which can result in a tear of the already compromised parenchymal tissue of the emphysematous ipsilateral lobe, resulting in a pneumothorax (criner et al.A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate).Am j respir crit care med.2018; 198 (9): 1151-1164).In the liberate study (ide clinical study used to support pma p180002's approval), 26.6% of the zephyr valve subjects experienced a pneumothorax in the treatment period ([less than or equal to 45 days).These were managed using standard of care procedures as per previously published guidelines (valipour, arschang, et al.Respiration 87.6 (2014): 513-521).In 17.4% of the events, the pneumothorax resolved without any additional intervention with subjects under careful observation.In over half the events (56.5%), the pneumothorax was managed with a chest-tube only.An additional 13% of the events were managed with a chest-tube and the temporary removal of one or more valves, while another 13% of the events were managed with a chest-tube and removal of all the implanted valves.Upon successful resolution of the pneumothorax, removed valves can be replaced.Patients that experienced a pneumothorax experienced clinical benefits of the zephyr valve treatment that were similar to the benefits experienced by patients who did not have a pneumothorax.The zephyr ebv system ifu and pulmonx training program both specifically reference pneumothorax as a known side effect of this procedure and the published guidelines (valipour, arschang, et al."expert statement: pneumothorax associated with endoscopic valve therapy for emphysema-potential mechanisms, treatment algorithm, and case examples." respiration 87.6 (2014): 513-521).The reported event aligns with the experience observed in the liberate clinical study and is an expected side effect to the zephyr valve treatment.
 
Event Description
On (b)(6) 2022 the subject had zephyr valves placed in the left upper lobe.The patient developed a pneumothorax post-procedure, had aspirated, and became sceptic.All valves were removed on 11/19.Further information will be reported once available.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ZEPHYR ENDOBRONCHIAL VALVE (EBV)
Type of Device
ENDOBRONCHIAL VALVE
Manufacturer (Section D)
PULMONX CORPORATION
700 chesapeake drive
redwood city CA 94063
Manufacturer Contact
mahtab fatemi
700 chesapeake drive
redwood city, CA 94063
6504072823
MDR Report Key16040233
MDR Text Key306060196
Report Number3007797756-2022-00317
Device Sequence Number1
Product Code NJK
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P180002
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility,Company Representative
Reporter Occupation Non-Healthcare Professional
Remedial Action Patient Monitoring
Type of Report Initial
Report Date 12/22/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/22/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date02/25/2023
Device Model NumberZEPHYR 4.0-LP EBV
Device Catalogue NumberEBV-TS-4.0-LP
Device Lot Number505433-V7.1
Was Device Available for Evaluation? No
Date Manufacturer Received11/23/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured02/25/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Hospitalization;
-
-